- SynonymFIGF,VEGFD
- SourceHuman VEGF-D, His Tag (VED-H5228) is expressed from human 293 cells (HEK293). It contains AA Phe 93 - Ser 201 (Accession # AAH27948).Predicted N-terminus: Phe 93Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 13.4 kDa. The protein migrates as 19-22 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human VEGF-D, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) at 5 μg/mL (100 μL/well) can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with a linear range of 0.08-0.6 μg/mL (QC tested).
- BackgroundVascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.
- References
- (1)Leppanen V.M., et al., 2011, Blood 117:1507-1515.
- (2)Yamada Y., et al., 1997, Genomics 42 (3): 483–8.
- (3)Achen MG., et al., 1998, Proc. Natl. Acad. Sci. U.S.A. 95 (2): 548–53.
- (4)Yasuoka H., et al., 2005, Mod. Pathol. 18 (8): 1127–33.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
eFluoro450,APCh7,PeCy5,PeCy7
过表达质粒转染细胞,以空载质粒做对照,48h后检测对凋亡的影响。请问定象限的时候是用空载质粒的对照组,还是需要用未转染的正常细胞?
在流式细胞仪中,用PI单染法区分死细胞和活细胞,怎么看数据结果?
(溶血):红细胞,血红蛋白分解,红细胞溶解逃逸所述,称为溶血。通过各种物理和化学因素和毒素。在体外,如低渗溶液中,强烈的机械振荡,突然冷冻(-20℃-25℃)或突然化冻,过酸或过碱,以及乙醇,乙醚,皂碱,胆碱盐可引起溶血。人血浆的等渗溶液为0.9%NaCl溶液,红细胞在低于0.45%的NaCl溶液中,由于水的渗透,肿胀和红细胞破裂,血红蛋白逸出。在体内,溶血溶血性细菌侵入或某些毒素的抗原 - 抗体反应(如输入配血不合的血液),各种机械性损伤,红细胞内在(膜,酶)引起某些药物的缺陷。溶血性细菌,如某些溶血性链球菌和产气荚膜梭菌可导致败血症。的红血细胞和某些溶血性毒液含酶卵磷脂,卵磷脂血浆或红细胞成溶血卵磷脂,使红细胞膜分解疟原虫破坏。
取对数生长期的细胞,按1X106个/mL以1mL体积接种于6孔板内。培养24h后,加入不同浓度样品。在37 ℃、5 % 的CO2恒温箱中培养24h后终止。
(2)细胞固定
胰酶消化并离心收集细胞(800rpm/min),弃上清,用预冷PBS洗细胞两次,加入预冷70%乙醇, -20℃固定保存。
(3) 细胞染色
离心收集细胞(800rpm/min),以1mL的PBS洗细胞一次,加入500uLPBS含50ug/mL溴化乙锭(PI),100ug/mL RNase A, 4℃避光孵育20分钟。
(4)检测
以标准程序用流式细胞仪检测,汞激发波长488nm,计数8千个细胞,结果用软件WinMDI Version 2.9分析。